PE20001087A1 - ORAL DOSE FORMULATIONS INCLUDING (2S, 3S, 5R) -2- (3,5-DIFLUOROPHENYL) -3,5-DIMETHYL-2-MORPHOLINOL AND ALGINIC ACID - Google Patents
ORAL DOSE FORMULATIONS INCLUDING (2S, 3S, 5R) -2- (3,5-DIFLUOROPHENYL) -3,5-DIMETHYL-2-MORPHOLINOL AND ALGINIC ACIDInfo
- Publication number
- PE20001087A1 PE20001087A1 PE1999000976A PE00097699A PE20001087A1 PE 20001087 A1 PE20001087 A1 PE 20001087A1 PE 1999000976 A PE1999000976 A PE 1999000976A PE 00097699 A PE00097699 A PE 00097699A PE 20001087 A1 PE20001087 A1 PE 20001087A1
- Authority
- PE
- Peru
- Prior art keywords
- morpholinol
- difluorophenyl
- dimethyl
- alginic acid
- formulations including
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000000783 alginic acid Substances 0.000 title abstract 2
- 235000010443 alginic acid Nutrition 0.000 title abstract 2
- 229920000615 alginic acid Polymers 0.000 title abstract 2
- 229960001126 alginic acid Drugs 0.000 title abstract 2
- 150000004781 alginic acids Chemical class 0.000 title abstract 2
- OZGPVYJHWWPEFT-RGNHYFCHSA-N manifaxine Chemical compound C[C@@H]1N[C@H](C)CO[C@@]1(O)C1=CC(F)=CC(F)=C1 OZGPVYJHWWPEFT-RGNHYFCHSA-N 0.000 title abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 abstract 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 206010012335 Dependence Diseases 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 241000208125 Nicotiana Species 0.000 abstract 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 abstract 1
- -1 SACAROSE Chemical compound 0.000 abstract 1
- 235000021355 Stearic acid Nutrition 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 229940049654 glyceryl behenate Drugs 0.000 abstract 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 229960002715 nicotine Drugs 0.000 abstract 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 abstract 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940079832 sodium starch glycolate Drugs 0.000 abstract 1
- 229920003109 sodium starch glycolate Polymers 0.000 abstract 1
- 239000008109 sodium starch glycolate Substances 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 239000008117 stearic acid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A FORMULACIONES ORALES QUE COMPRENDE: a)AL MENOS 0.25 mg DE (2S,3S,5R)-2-(3,5-DIFLUOROFENIL)-3,5-DIMETIL-2-MORFOLINOL DE FORMULA I, UNA SAL CLORHIDRATO, UN SOLVATO o UN SOLVATO DE LA SAL; b)AL MENOS 0,2% EN PESO DE UNA CANTIDAD ESTABILIZANTE EFECTIVA DE ACIDO ALGINICO; c)40% A 95% EN PESO DE UN PORTADOR TAL COMO MANITOL, SACAROSA, LACTOSA Y CELULOSA MICROCRISTALINA; d)DE 0,1% A 5% DE UN LUBRICANTE TAL COMO BEHENATO DE GLICERILO, ESTEARATO DE MAGNESIO Y ACIDO ESTEARICO; e)DE 1% A 10% DE UNA GLUCOPIRANOSA O o ß TAL COMO GLICOLATO DE ALMIDON DE SODIO, DE BAJO pH. LAS FORMULACIONES PUEDEN SER UTILES PARA PREVENIR O TRATAR EL TRASTORNO HIPERCINETICO DE LA DEFICIENCIA DE LA ATENCION O DEPRESION, ADICCION A LOS PRODUCTOS QUE CONTIENEN NICOTINA ESPECIALMENTE TABACOREFERS TO ORAL FORMULATIONS INCLUDING: a) AT LEAST 0.25 mg OF (2S, 3S, 5R) -2- (3,5-DIFLUOROPHENYL) -3,5-DIMETHYL-2-MORPHOLINOL OF FORMULA I, A HYDROCHLORIDE SALT, A SOLVATE or A SOLVATE OF SALT; b) AT LEAST 0.2% BY WEIGHT OF AN EFFECTIVE STABILIZING AMOUNT OF ALGINIC ACID; c) 40% TO 95% BY WEIGHT OF A CARRIER SUCH AS MANNITOL, SACAROSE, LACTOSE AND MICROCRYSTALLINE CELLULOSE; d) FROM 0.1% TO 5% OF A LUBRICANT SUCH AS GLYCERYL BEHENATE, MAGNESIUM STEARATE AND STEARIC ACID; e) FROM 1% TO 10% OF A GLUCOPYRANOSE O or ß SUCH AS SODIUM STARCH GLYCOLATE, LOW pH. FORMULATIONS MAY BE USEFUL TO PREVENT OR TREAT THE HYPERKINETIC DISORDER OF ATTENTION DEFICIENCY OR DEPRESSION, ADDICTION TO PRODUCTS CONTAINING NICOTINE, ESPECIALLY TOBACCO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10211298P | 1998-09-28 | 1998-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20001087A1 true PE20001087A1 (en) | 2000-10-20 |
Family
ID=22288187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1999000976A PE20001087A1 (en) | 1998-09-28 | 1999-09-27 | ORAL DOSE FORMULATIONS INCLUDING (2S, 3S, 5R) -2- (3,5-DIFLUOROPHENYL) -3,5-DIMETHYL-2-MORPHOLINOL AND ALGINIC ACID |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1117407A1 (en) |
| JP (1) | JP2002525328A (en) |
| KR (1) | KR20010075385A (en) |
| CN (1) | CN1328459A (en) |
| AR (1) | AR022673A1 (en) |
| AU (1) | AU6087399A (en) |
| BR (1) | BR9914096A (en) |
| CA (1) | CA2345638A1 (en) |
| CZ (1) | CZ20011142A3 (en) |
| HU (1) | HUP0103459A2 (en) |
| IL (1) | IL142054A0 (en) |
| MA (1) | MA26693A1 (en) |
| NO (1) | NO20011555L (en) |
| PE (1) | PE20001087A1 (en) |
| PL (1) | PL346877A1 (en) |
| TR (1) | TR200100863T2 (en) |
| WO (1) | WO2000018406A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7750100A (en) * | 1999-10-13 | 2001-04-23 | Glaxo Group Limited | Method for the treatment of obesity |
| DE102008047910A1 (en) | 2008-09-19 | 2010-03-25 | Molkerei Meggle Wasserburg Gmbh & Co. Kg | Tabletting excipient based on lactose and cellulose |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4597969A (en) * | 1982-04-05 | 1986-07-01 | Merck Sharp & Dohme | Stabilization of unstable drugs or food supplements |
| GB8924528D0 (en) * | 1989-10-31 | 1989-12-20 | Wellcome Found | Heterocyclic pharmaceutical compounds,preparation and use |
-
1999
- 1999-09-23 MA MA25782A patent/MA26693A1/en unknown
- 1999-09-24 TR TR2001/00863T patent/TR200100863T2/en unknown
- 1999-09-24 IL IL14205499A patent/IL142054A0/en unknown
- 1999-09-24 KR KR1020017003874A patent/KR20010075385A/en not_active Withdrawn
- 1999-09-24 PL PL99346877A patent/PL346877A1/en unknown
- 1999-09-24 HU HU0103459A patent/HUP0103459A2/en unknown
- 1999-09-24 BR BR9914096-9A patent/BR9914096A/en not_active IP Right Cessation
- 1999-09-24 JP JP2000571924A patent/JP2002525328A/en active Pending
- 1999-09-24 CA CA002345638A patent/CA2345638A1/en not_active Abandoned
- 1999-09-24 AU AU60873/99A patent/AU6087399A/en not_active Abandoned
- 1999-09-24 CN CN99813675A patent/CN1328459A/en active Pending
- 1999-09-24 EP EP99947420A patent/EP1117407A1/en not_active Withdrawn
- 1999-09-24 WO PCT/EP1999/007117 patent/WO2000018406A1/en not_active Ceased
- 1999-09-24 AR ARP990104841A patent/AR022673A1/en unknown
- 1999-09-24 CZ CZ20011142A patent/CZ20011142A3/en unknown
- 1999-09-27 PE PE1999000976A patent/PE20001087A1/en not_active Application Discontinuation
-
2001
- 2001-03-27 NO NO20011555A patent/NO20011555L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20011555D0 (en) | 2001-03-27 |
| CA2345638A1 (en) | 2000-04-06 |
| KR20010075385A (en) | 2001-08-09 |
| MA26693A1 (en) | 2004-12-20 |
| IL142054A0 (en) | 2002-03-10 |
| PL346877A1 (en) | 2002-03-11 |
| AR022673A1 (en) | 2002-09-04 |
| CZ20011142A3 (en) | 2001-09-12 |
| EP1117407A1 (en) | 2001-07-25 |
| NO20011555L (en) | 2001-03-27 |
| AU6087399A (en) | 2000-04-17 |
| BR9914096A (en) | 2001-07-31 |
| CN1328459A (en) | 2001-12-26 |
| HUP0103459A2 (en) | 2002-01-28 |
| WO2000018406A1 (en) | 2000-04-06 |
| TR200100863T2 (en) | 2001-07-23 |
| JP2002525328A (en) | 2002-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX9207169A (en) | ORAL COMPOSITIONS TO SUPPRESS ORAL ODORS. | |
| CY1106634T1 (en) | THERAPEUTIC DERIVATIVES OF PIPERAZINE | |
| UY24308A1 (en) | BINDER-FREE TABLETS CONTAINING TRAMADOL OR A SALT OF TRAMADOL, FOR ORAL ADMINISTRATION | |
| GR3031135T3 (en) | Compositions containing S(+)-Ibuprofen. | |
| YU23599A (en) | Stabilized antihistamine syrup | |
| KR890011592A (en) | Composition for the treatment of endotracheal ischemia | |
| BR9810312A (en) | Pharmaceutical composition that has marked antitumor activity and / or reduced side effects containing an antitumor agent and a derivative of hydroxy acid | |
| FI943315A0 (en) | Pharmaceutical preparation in the form of an effervescent and / or disintegrating tablet or granules, as well as a process for their preparation | |
| ES2063093T3 (en) | ORAL COMPOSITIONS. | |
| AU6593301A (en) | Compounds with a sulphonamide group and pharmaceutical compositions containing these compounds | |
| EP1222922A4 (en) | Method for stabilizing benzimidazole compounds | |
| RU94044456A (en) | Agent for suppression of dysfunctional uterine bleeding | |
| BR8400234A (en) | BENZOYLUREA COMPOUNDS, PROCESS FOR THE PREPARATION OF BENZOYLUREA COMPOUNDS, COMPOSITION HAVING INSECTICIDE AND ACARICIDE ACTIVITY, PHARMACEUTICAL COMPOSITION, PROCESS FOR THE PREPARATION OF A COMPOSITION HAVING INSECTICATED AND CAREED ACTIVITY AND PROCESSING TO PROTECT OR INSERT AND PROCESS TO PROTECT OR CONTROL THE PROCESS ALIVE | |
| DE69031340D1 (en) | ANTIVIRAL COMPOSITIONS CONTAINING 3'-AZIDO-2 ', 3'-DIDEOXY-5-METHYLCYTIDINE | |
| ES2087623T3 (en) | DERIVATIVES OF BENCIMIDAZOLE AS AN ANTIMICROBIAL AGENT AGAINST CAMPYLOBACTER PYLON. | |
| EP1123701A4 (en) | NATURAL PHYSIOLOGICALLY ACTIVE SUBSTANCES ACTING AGAINST DISEASES OF FISH AND FISH FOOD CONTAINING SUCH SUBSTANCES | |
| BR0311642A (en) | Increased Release Sodium Divalproex Formulation | |
| PE20001087A1 (en) | ORAL DOSE FORMULATIONS INCLUDING (2S, 3S, 5R) -2- (3,5-DIFLUOROPHENYL) -3,5-DIMETHYL-2-MORPHOLINOL AND ALGINIC ACID | |
| PT913151E (en) | FIGHTING COMPOUNDS AGAINST HELICOBACTER PYLORI CONTAINING 1-MEZLCARBAPENEM DERIVATIVES AS AN ACTIVE SUBSTANCE | |
| ES475533A1 (en) | Novel propione amide derivative and its manufacture | |
| ES2123808T3 (en) | DERIVATIVE OF ACILFENILGLICINA AND PROPHYLCITIC AND CURATIVE AGENT FOR DISEASES CAUSED BY AN INCREASED ACTIVITY OF COLAGENASE, WHICH CONTAINS SUCH COMPOUND AS AN ACTIVE INGREDIENT. | |
| ES2113136T3 (en) | PHARMACEUTICAL COMPOSITIONS OF GEMFIBROZIL AND PROCEDURE FOR ITS PREPARATION. | |
| ES2067206T3 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING 3-AMINO-EPSILON-CAPROLACTAMAS TO STIMULATE THE LEARNING PROCESS AND MEMORY. | |
| SE9900190D0 (en) | New compounds | |
| CA2345364A1 (en) | Use of bisphosphonic acid derivatives for preparing a medicine for treating lameness |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |